Top

Intensive Care Medicine

Published in:

01-08-2006 | Brief Report

Association of statin therapy and increased survival in patients with multiple organ dysfunction syndrome

Authors: Hendrik Schmidt, Ralf Hennen, Alexander Keller, Martin Russ, Ursula Müller-Werdan, Karl Werdan, Michael Buerke

Published in: Intensive Care Medicine | Issue 8/2006

Abstract

Objective

The multiple organ dysfunction syndrome (MODS) is the sequential failure of several organ systems after a trigger event, such as sepsis, pneumonia or cardiogenic shock. Even today, mortality is high. Statin therapy is associated with reduction of inflammation and subsequent rates of severe sepsis and ICU admission of patients admitted to hospital with presumed or documented acute bacterial infection. Our study aimed to characterize a potential survival benefit by statin therapy in MODS patients.

Design

Retrospective cohort study.

Setting

Twelve-bed medical intensive care unit in a university center.

Patients

Forty score-defined MODS patients under statin treatment and 80 age- and sex-matched score-defined MODS patients without statin treatment. Inclusion criterion was an APACHE II score ≥ 20 at admission to ICU.

Interventions

Assessment of statin treatment and calculation of disease severity by scoring. The patients were followed up for 28-day mortality as well as for hospital mortality.

Measurements and results

The MODS severity was equally pronounced in both groups. There were 42/80 deaths in the group without statin treatment and 13/40 deaths in the statin group (28-day mortality 53% vs. 33%, p = 0.03). Cox proportional hazard analysis revealed a hazard ratio of 0.53 (95% CI 0.29–0.99, p = 0.04). Hospital mortality was calculated at 72% (non-statin group) vs. 35% (statin group; chi-square  = 15.6, p < 0.0001). The overall hospital mortality was 60%.

Conclusions

Patients under statin treatment developing MODS might have a better outcome than patients without statin therapy, probably by reduction of inflammatory responses and increase of vagal activity in MODS.

Mekontso-Dessap A, Brun-Buisson C (2006) Statins: the next step in adjuvant therapy for sepsis? Intensive Care Med 32:11–14PubMedCrossRef

Merx MW, Weber C (2005) Statins: a preventive strike against sepsis in patients with cardiovascular disease? Lancet DOI: 10.1016/S0140–6736(06)

Warnholtz A, Genth-Zotz S, Münzel T (2005) Should treatment of sepsis include statins? Circulation 111:1735–1737PubMedCrossRef

Moerer O, Schmid A, Hofmann M, Herklotz A, Reinhart K, Werdan K, Schneider H, Burchardi H (2000) Direct costs of severe sepsis in three German intensive care units based on retrospective electronic patient record analysis of resource use. Intensive Care Med 28:1440–1446CrossRef

Pruefer D, Makowski J, Schnell M, Buerke U, Dahm M, Oelert H, Sibelius U, Grandel U, Grimminger F, Seeger W, Meyer J, Darius H, Buerke M (2002) Simvastatin inhibits inflammatory properties of Staphylococcus aureus alpha-toxin. Circulation 106:2104–2110PubMedCrossRef

Merx MW, Liehn EA; Janssens U, Lütticken R, Schrader J, Hanrath P, Weber C (2004) HMG-CoA reductase inhibitor simvastatin profoundly improves survival in a murine model of sepsis. Circulation 109:2560–2565PubMedCrossRef

Almog Y, Shefer A, Novack V, Maimon N, Barski L, Eizinger M, Friger M, Zeller L, Danon A (2004) Prior statin therapy is associated with a decreased rate of severe sepsis. Circulation 110:880–885PubMedCrossRef

Kruger P, Fitzsimmons K, Cook D, Jones M, Nimmo G (2006) Statin therapy is associated with fewer deaths in patients with bacteraemia. Intensive Care Med 32:75–79PubMedCrossRef

Schmidt H, Hennen R, Keller A, Rauchhaus M, Russ M, Mueller-Werdan U, Werdan K, Buerke M (2005) Association of statin therapy and increased survival in patients with multiple organ dysfunction syndrome. Intensive Care Med 31 [Suppl 1]: A10

10.

Schmidt H, Müller-Werdan U, Hoffmann T, Francis DP, Piepoli MF, Rauchhaus M, Prondzinsky R, Loppnow H, Buerke M, Hoyer D, Werdan K (2005) Autonomic dysfunction predicts mortality in patients with multiple organ dysfunction syndrome of different age groups. Crit Care Med 33:1994–2002PubMedCrossRef

11.

Schmidt H, Müller-Werdan U, Nuding S, Hoffmann T, Francis DP, Hoyer D, Rauchhaus M, Werdan K (2004) Impaired chemoreflex sensitivity in adult patients with multiple organ dysfunction syndrome – the potential role of disease severity. Intensive Care Med 30:665–672PubMedCrossRef

12.

Hackam DG,Mamdani M, Li P, Redelmeier DA (2006) Statins and sepsis in patients with cardiovascular disease: a population-based cohort analysis. Lancet 367:413–418PubMedCrossRef

13.

Liappis AP, Kan VL, Rochester CG, Simon GL (2001) The effect of statins on mortality in patients with bacteremia. Clin Infect Dis 33:1352–1357PubMedCrossRef

14.

Fernandez R, De Pedro VJ, Artigas A (2006) Statin therapy prior to ICU admission: protection against infection or a severity marker? Intensive Care Med 32:160–164PubMedCrossRef

15.

Steiner S, Speidl WS, Pleiner J, Seidinger D, Zorn G, Kaun C, Wojta J, Huber K, Minar E, Wolzt M, Kopp CW (2005) Simvastatin blunts endotoxin-induced tissue factor in vivo. Circulation 111:1841–1846PubMedCrossRef

16.

Tracey KJ (2002) The inflammatory reflex. Nature 420:853–859PubMedCrossRef

Title: Association of statin therapy and increased survival in patients with multiple organ dysfunction syndrome
Authors: Hendrik Schmidt
Ralf Hennen
Alexander Keller
Martin Russ
Ursula Müller-Werdan
Karl Werdan
Michael Buerke
Publication date: 01-08-2006
Publisher: Springer-Verlag
Published in: Intensive Care Medicine / Issue 8/2006
Print ISSN: 0342-4642
Electronic ISSN: 1432-1238
DOI: https://doi.org/10.1007/s00134-006-0246-y

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Association of statin therapy and increased survival in patients with multiple organ dysfunction syndrome

Abstract

Objective

Design

Setting

Patients

Interventions

Measurements and results

Conclusions

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Objective

Design

Setting

Patients

Interventions

Measurements and results

Conclusions

Please log in to get access to this content

Other articles of this Issue 8/2006

Soluble triggering receptor expressed on myeloid cells 1: a biomarker for bacterial meningitis

Is the measurement of monocytes HLA-DR expression useful in patients with sepsis?

DTPA Fe(III) decreases cytokines and hypotension but worsens survival with Escherichia coli sepsis in rats

The prevalence and characteristics of anaemia at discharge home after intensive care

Adrenal axis function does not appear to be associated with hemodynamic improvement in septic shock patients systematically receiving glucocorticoid therapy

Consensus guidelines on sedation and analgesia in critically ill children